Literature DB >> 24668753

Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation.

Yujiao Jia1, Leiwen Peng1, Qing Rao1, Haiyan Xing1, Lei Huai1, Pei Yu1, Yirui Chen1, Cuicui Wang1, Min Wang1, Yingchang Mi1, Jianxiang Wang2.   

Abstract

iASPP is a member of the apoptosis-stimulating proteins of p53 (ASPP) family and negatively regulates the apoptotic function of p53. In a hematopoietic system, overexpression of iASPP results in blockage of apoptosis, which may play a role in regulating hematopoietic stem cell (HSC) numbers. To address this, we first analyzed the expression of iASPP in patients with acute leukemia (AL) and found it was highly expressed in patients with AL. We further established a transgenic mouse model in which human iASPP was specifically expressed in hematopoietic cells. Overexpression of iASPP led to an increase in the proportion of long-term HSCs, short-term HSCs, multipotent progenitors, and common myeloid progenitor. HSCs from iASPP transgenic mice had an advantage in long-term reconstitution potential. In addition, the hematopoietic cells from iASPP transgenic mice exhibited a significantly lower level of p53 dependent apoptosis. After irradiation damage, hematopoietic cells of iASPP transgenic mice had a higher level of γ-H2AX expression, which lasted for a longer time. These results provide the first evidence that the iASPP can increase HSC populations and reconstitution capacity. Interestingly, in response to cell damage stimuli, hematopoietic cells can be protected against apoptosis by iASPP; meanwhile these apoptosis-resistant cells would have more mutation accumulation, which might be the potential risk for malignant transformation.-Jia, Y., Peng, L., Rao, Q., Xing, H., Huai, L., Yu, P., Chen, Y., Wang, C., Wang, M., Mi, Y., Wang, J. Oncogene iASPP enhances self-renewal of hematopoietic stem cells and facilitates their resistance to chemotherapy and irradiation. © FASEB.

Entities:  

Keywords:  HSC; antiapoptosis; self-renewal; transgenic

Mesh:

Substances:

Year:  2014        PMID: 24668753     DOI: 10.1096/fj.13-244632

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

1.  A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.

Authors:  Huayi Li; Wenxin Zhang; Kunming Zhao; Dong Zhao; Shanliang Zheng; Ying Hu
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

2.  Flexible Tethering of ASPP Proteins Facilitates PP-1c Catalysis.

Authors:  Yeyun Zhou; Robyn Millott; Hyeong Jin Kim; Shiyun Peng; Ross A Edwards; Tamara Skene-Arnold; Michal Hammel; Susan P Lees-Miller; John A Tainer; Charles F B Holmes; J N Mark Glover
Journal:  Structure       Date:  2019-08-08       Impact factor: 5.006

3.  iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.

Authors:  Dong Zhao; Shanliang Zheng; Xingwen Wang; Hao Liu; Kunming Zhao; Li Li; Ying Hu
Journal:  Oncogene       Date:  2022-02-15       Impact factor: 8.756

4.  Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells.

Authors:  Shaowei Qiu; Shuang Liu; Tengteng Yu; Jing Yu; Min Wang; Qing Rao; Haiyan Xing; Kejing Tang; Yinchang Mi; Jianxiang Wang
Journal:  BMC Cancer       Date:  2017-11-28       Impact factor: 4.430

5.  FHL2 interacts with iASPP and impacts the biological functions of leukemia cells.

Authors:  Wenting Lu; Tengteng Yu; Shuang Liu; Saisai Li; Shouyun Li; Jia Liu; Yingxi Xu; Haiyan Xing; Zheng Tian; Kejing Tang; Qing Rao; Jianxiang Wang; Min Wang
Journal:  Oncotarget       Date:  2017-06-20

6.  iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.

Authors:  Ying Xiong; Fei Sun; Peixin Dong; Hidemichi Watari; Junming Yue; Min-Fei Yu; Chun-Yan Lan; Yin Wang; Ze-Biao Ma
Journal:  J Exp Clin Cancer Res       Date:  2017-04-11

7.  Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB.

Authors:  Ying Hu; Wenjie Ge; Xingwen Wang; Gopinath Sutendra; Kunming Zhao; Zinaida Dedeić; Elizabeth A Slee; Caroline Baer; Xin Lu
Journal:  Oncotarget       Date:  2015-12-15

Review 8.  Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors.

Authors:  Peixin Dong; Kei Ihira; Junichi Hamada; Hidemichi Watari; Takahiro Yamada; Masayoshi Hosaka; Sharon J B Hanley; Masataka Kudo; Noriaki Sakuragi
Journal:  Oncotarget       Date:  2015-08-21

9.  Mild Therapeutic Hypothermia Protects the Brain from Ischemia/Reperfusion Injury through Upregulation of iASPP.

Authors:  Xiangrong Liu; Shaohong Wen; Shunying Zhao; Feng Yan; Shangfeng Zhao; Di Wu; Xunming Ji
Journal:  Aging Dis       Date:  2018-06-01       Impact factor: 6.745

10.  iASPP overexpression is associated with clinical outcome in spinal chordoma and influences cellular proliferation, invasion, and sensitivity to cisplatin in vitro.

Authors:  Yunlong Ma; Bin Zhu; Xiaoguang Liu; Zhongjun Liu; Liang Jiang; Feng Wei; Miao Yu; Fengliang Wu; Hua Zhou; Nanfang Xu; Xiao Liu; Lei Yong; Yongqiang Wang; Peng Wang; Chen Liang; Guanping He
Journal:  Oncotarget       Date:  2017-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.